Diagnostics and Companion Diagnostics for Translational Research and Precision Medicine
Acobiom is specialized in the discovery of new biomarkers and the development of innovative diagnostics dedicated to Translational Research and Precision Medicine.
The company has developed a state-of-art technology platform that associates Next-Generation Sequencing (NGS) and proprietary Bioinformatics, and is dedicated to RNA/DNA Biomarker discovery.
These Biomarkers identified from the analysis of gene expression changes or biological phenotypes could be applied in several activities including: companion diagnosis, disease detection and classification, patient stratification, treatment response prediction, disease prognosis.
Acobiom is positioned in the field of Precision Medicine, which takes people’s biological and physiological differences into account in order to administer the most effective treatment or the most (+)
Our approach to discover new Biomarkers
Acobiom is involved and has been involved in clinical studies (and clinical trials) to identify (Blood) Biomarkers, that will make it possible to identify (+)
Due to its expertise in Next-Generation Sequencing (NGS) technologies, genomics, transcriptomics and bioinformatics, Acobiom is currently involved in several developments concerning Precision Medicine, Companion Diagnostics and patient stratification tests, which (+)
Acobiom is involved or has recently been involved in different research programs, including several projects granted by the European Commission (FP6, FP7), Bpifrance and ANR:
OncoSNIPE: Development of diagnostics/pronostics of (+)